CN5 COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU) IN GERMANY  by Schuler, US et al.
A224 Paris Abstracts
patients with T2DM in the UK had signiﬁcantly lower (p  0.0001) physical summary 
scores than other EU countries. Patients experiencing depression symptoms were more 
likely to visit the ER [OR  1.74; 95% CI:(1.35, 2.23); p  0.0001], be hospitalized 
[OR  1.43; 95% CI:(1.11, 1.84); p  0.005] and had more physician visits in the last 
six months (B  5.37, p  0.0001). Patients in Spain had signiﬁcantly more provider 
visits (p  0.05) and ER visits (p  0.0001) than UK patients, while patients in France 
were hospitalized more often than UK patients (p  0.05). CONCLUSIONS: Comor-
bid depression in patients with T2DM greatly decreases physical and mental summary 
scores of the SF-12, and increases resource use. Further research is needed to clarify 
associations between the two conditions, including geographical and cultural inﬂu-
ences on health outcomes in this cohort.
PODIUM SESSION I: UTILITY MEASUREMENTS STUDIES
UT1
VALUING EQ-5D USING TIME TRADE-OFF IN FRANCE
Chevalier J1, De Pouvourville G2
1Institut Gustave Roussy, Villejuif Cedex, France, 2ESSEC Business School, Cergy Pontoise 
Cedex, France
OBJECTIVES: The EQ-5D questionnaire has been developed and validated in France 
but the utility function has not been elicited. The main objective of the present study 
is to provide a French value-set for the EQ-5D health states using the Time Trade-Off 
(TTO) method. METHODS: A total of 452 respondents aged over 18 were recruited 
for a French valuation study. They were chose to be representative of the French 
population with regard to age, gender and socio-professional group. Twenty four 
EQ-5D health states were selected to be directly valued. Three groups of 300 respon-
dents were set up and each group valued 17 of 24 EQ-5D health states using the time 
trade-off (TTO) method. The TTO valuations were linearly transformed to lie on the 
interval [1;1]. Exclusion criteria used were the same as in other valuation studies. 
We also investigated logical inconsistencies. Several alternative models speciﬁcations 
were investigated to estimate the values of the remaining non direct valuated EuroQol 
health states. The analysis was conducted at an individual level to make the maximum 
use of the available data and we estimated mixed models with random intercept. 
Models were compared using different goodness of ﬁt measures: the Akaike’s informa-
tion criterion (AIC), the Mean Absolute Error (MAE) and the Pearson correlation 
between the observed and the predicted value. RESULTS: After exclusion, 443 respon-
dents take part in the study. Fifty three respondents (12%) present more than 10 
logical inconsistencies in their responses. The model presenting the smaller Akaike’s 
information criterion include the same variables as the N3-model used in UK. This 
model yield a good ﬁt for the TTO data with a mean absolute error of 0.04 and a 
Pearson correlation coefﬁcient of 0.99. CONCLUSIONS: This study will provide the 
ﬁrst EQ-5D value set for France.
UT2
PARADIGM LOST: A CONCEPTUAL AND EMPIRICAL OBITUARY 
CHRONICLING THE DEMISE OF CARDINAL UTILITY MEASUREMENTNT
Kind P
University of York, York, UK
OBJECTIVES: The choice of quality-adjustment factor, as stipulated by health eco-
nomics and as required by regulatory agencies, dictates that the “Q” in QALY should 
be a utility (choice-based preference) measure. This requirement has led to a state of 
chaos in which multiple utility elicitation methods are permitted and in which no test 
of their relative performance has been documented. This paper reﬂects the current 
status of utility measurement as applied in QALY calculations and conclusively dem-
onstrates its fallibility. METHODS: The paper is divided into two parts, the ﬁrst of 
which rehearses the basic measurement requirements for any viable metric used as a 
quality-adjustment scalar and deals with the impossibility of permitting mutually 
incompatible utility elicitation procedures. It concludes with a novel test of uniqueness 
that can be applied to competing sets of utility weights. The second part is based on 
empirical evidence generated in the MVH study in which both TTO and VAS ratings 
were used to calibrate EQ-5D for use in economic evaluation conducted in the UK 
(n  3395). Analysis compares the within-respondent ordinal preferences captured 
through VAS rating with those inferred by TTO utilities. RESULTS: Nearly 50% of 
respondents had a Spearmans rho below 0.8, corresponding to a mean difference in 
rank of around 4 between VAS and TTO scores. Twenty-six percent of respondents 
assigned a utility of 1.0 (full health) to 3 or more health states with differing degrees 
of dysfunction. More than 40% of respondents fail to distinguish between full health 
and the 5 mildest health states. CONCLUSIONS: The demonstrable frailty of utility 
elicitation methods is well-known. Research scientists in general and health economists 
in particular should be wary of encouraging others to accept QALY metrics of this 
type. The continued requirement for utility measures in social decision-making com-
promises both the science and the scientists who tolerate its misuse.
UT3
HEALTHY-DAYS TIME EQUIVALENTS FOR OUTCOMES OF ACUTE 
ROTAVIRUS INFECTIONS
Hauber AB1, Johnson FR1, Cook JR2, Mohamed AF1, Gonzalez JM1, Walter E3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Merck and Co. Inc, North Wales, 
PA, USA, 3Duke University, Durham, NC, USA
Conventional standard-gamble and time-tradeoff methods may be inappropriate for 
eliciting preferences for acute, nonfatal health states because both require subjects to 
evaluate tradeoffs between a morbid health state and death. OBJECTIVES: This study 
demonstrates the use of conjoint analysis with a discrete-choice experimental design 
to obtain estimates of healthy-days equivalents (HDEs) for clinically relevant durations 
and severities for rotavirus gastroenteritis, an acute diarrheal illness common in young 
children. METHODS: Parents of children a5 years of age completed a web-enabled 
survey instrument that presented a series of trade-off questions to elicit judgments 
about the relative seriousness of pairs of hypothetical gastrointestinal illnesses. Each 
illness was deﬁned by seven attributes: diarrhea, vomiting, fever, seizure, behavioral 
changes, dehydration, and illness duration. A random-parameters ordered-probit 
model was developed to estimate the preference weights for each symptom-severity 
level. RESULTS: A total of 229 parents completed the survey. Subjects judged seizure 
to be the worst rotavirus symptom, followed by dehydration, vomiting, fever, and 
diarrhea. Parents rated behavioral changes as the least bothersome symptom of rota-
virus. Estimated preference weights indicate improvements in each symptom relative 
to its worst level. As the duration of the illness increases, so does the decrement in 
HDEs. The decreases in time equivalents for 3-day and 7-day illnesses with seizure 
are 0.7 and 2.3 HDEs, respectively, while the corresponding decreases for illnesses 
with diarrhea are 0.3 and 1.0 HDE, respectively. These results imply that seizure is 
subjectively about 2.3 times more important than nine loose bowel movements per 
day. CONCLUSIONS: Results indicate that the trade-off data support valid estimates 
of HDEs for acute conditions ranging in duration from one day to two weeks without 
requiring subjects to make implausible comparisons between acute, self-limiting condi-
tions and mortality risks or longevity reductions.The results can be used for cost-
effectiveness analysis in place of conventional time-equivalents.
UT4
DEVELOPING AND PRELIMINARY TESTING OF AN OFFICIAL FIVE-
LEVEL VERSION OF EQ-5D
Herdman M1, Gudex C2, Lloyd A3, Janssen B4, Kind P5, Parkin D6, Bonsel GJ7, Badia X8
1Insight Consulting & Research, Mataró, Barcelona, Spain, 2Odense University Hospital, 
Odense, Denmark, 3Oxford Outcomes Ltd, Oxford, Oxfordshire, UK, 4EuroQol Group 
Executive Ofﬁce, Rotterdam, The Netherlands, 5University of York, York, UK, 6City 
University, London, UK, 7Erasmus Medical Centre, Rotterdam, n/a, The Netherlands,  
8IMS Health, Barcelona, Spain
OBJECTIVES: To select and test severity labels for a new, ﬁve-level version of the 
EQ-5D. METHODS: The EQ-5D is a generic instrument for describing and valuing 
health. Each dimension (Mobility, Self-Care, Usual activities, Pain/discomfort, 
Anxiety/depression) is currently measured on 3 levels of health (no problems, some 
problems, extreme problems). A EuroQol Group task force was established to ﬁnd 
ways of improving the instrument’s sensitivity to small and medium changes in health 
and reducing the ceiling effect. The study used a two-stage approach: i) response 
scaling was performed in the UK and Spain to explore the severity represented by 
potential new labels that could be used as additional or replacement levels within each 
dimension. Labels as close as possible to the 25th, 50th and 75th centiles were selected 
for further testing; ii) the face and content validity of alternative 5-level versions were 
investigated in 8 focus groups of healthy participants and patients in each country. 
Hypothetical health states based on a revised labeling system were also reviewed. 
RESULTS: Rank ordering of severity labels was similar across dimensions and coun-
tries. Selecting labels at approximately the 25th, 50th and 75th centiles produced two 
alternative 5-level versions. Focus group work showed a slight preference for the 
wording ‘slight-moderate-severe’ problems, with anchors of ‘no problems’ and ‘unable 
to do’ in the EQ-5D functional dimensions. Similar wording was used in the Pain/dis-
comfort and Anxiety/depression dimensions. Focus group comments indicated that, 
although not always colloquial, the magnitude of problems represented by the new 
labels was well understood. Comments on hypothetical health states referred more 
to their internal consistency than to the labels, which were again well understood. 
CONCLUSIONS: This study represents the ﬁrst step towards developing an ofﬁcial 
5-level version of the EQ-5D. Testing in patient settings and development of the cor-
responding health state valuations is required.
PODIUM SESSION II: CANCER STUDIES II
CN5
COSTS OFT QALYS GAINED IN A PALLIATIVE CARE UNIT (PCU)  
IN GERMANY
Schuler US1, Schubert BT2, Haag C1
1University of Dresden, Dresden, Saxony, Germany, 2St. Joseph Stift Hospital, Dresden, 
Saxony, Germany
The concept of QALYs has been introduced to compare therapies in widely separated 
areas of medicine. Many of the more recent developments in oncology are considered 
too costly in terms of prices for an additional QALY gained. Here we try to apply 
the concept to PCU-care in Germany, an area, with a high proportion of oncology 
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patients. A typical PCU admits patients in the ﬁnal phase of life. A high quality of 
care by a multi disciplinary team (including nurses, physicians, psychologists, music 
therapy, physiotherapy and others) results in substantial costs (recent survey in 
German PCUs: on average ~a400/day). The average length of stay is in the range of 
11–15 days, the proportion of discharged patients varies between 40–70%, for the 
remaining patients the admission ends not unexpectedly with the death of the patients. 
The gain in utility close to death is difﬁcult to estimate, but even high assumptions 
(e.g. 0,5) result in costs for QALYs, which are unexpectedly high. Scenario 1: 14, 0.5, 
30, 0.5, 400, 192455 a; scenario 2: 14, 0.7,30, 0.5, 400, 172545 a; scenario 3: 14, 
0.5, 30, 0.3, 400, 320758 a; scenario 4: 10, 0.5, 30, 0.5, 400, 182500 a for length of 
stay (d), proportion surviving, survival after discharge (d), gain in utility, cost/day, 
resulting cost / QALY. People experiencing the sheer necessity of palliative care for a 
death with dignity may use these data as an argument against the QALY concept. 
Only by including longterm changes e.g. in the utility gain experienced by relatives 
(small gains over a long period in several persons, e.g. by avoiding pathological grief) 
the model results in costs/QALY which seem acceptable.
CN6
TREATMENT-RELATED TOXICITIES IN PATIENTS WITH SQUAMOUS 
CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
Yood MU1, Wang F2, Zhao Z2, Alford SH3, Oliveria S1, Wells K3, Phillips S4, Ali H3, 
O’Malley C5, Barber B6
1Epi Source, hamden, CT, USA, 2Amgen Inc, Thousand Oaks, CA, USA, 3Henry Ford Health 
System, Detroit, MI, USA, 4Epi Source, Hamden, CT, USA, 5Amgen, Inc, Thousand Oaks, 
CA, USA, 6Amgen Inc., Thousand Oaks, CA, USA
OBJECTIVES: To evaluate treatment-related toxicities among patients with squamous 
cell carcinoma of the head and neck (SCCHN) treated in real-world clinical practices. 
METHODS: We used a population-based tumor registry at a large, US health system, 
to identify all cases of stage III or IV SCCHN diagnosed from 2000 to 2006. We 
identiﬁed the incidence/severity of acute and late toxicities associated with SCCHN 
treatment from detailed medical record reviews. Acute and late toxicities were evalu-
ated using CTCAE3 criteria and RTOG/EORTC late radiation morbidity scoring 
scheme, respectively. The incidence and severity of toxicities are presented by treat-
ments. Detailed analyses according to tumor stage and location, grade, and acute 
versus late events were examined. RESULTS: We identiﬁed 195 patients with SCCHN: 
A total of 104 patients (53%) received chemotherapy (chemo)  radiation therapy 
(RT); 87 (45%) received RT only; four patients (2%) received chemotherapy only or 
other/no treatment. Adverse Events of Interest (grade 2–4) by Treatment Received (N 
 191*): Gastrointestinal: 160 (83.8), 89 (85.6), 71 (81.6); Xerostomia: 61 (31.9), 41 
(39.4), 20 (23.0); Dysphagia: 70 (36.6), 44 (42.3), 26 (29.9); Dermatology: 91 (47.6), 
54 (51.9), 37 (42.5); Pulmonary: 74 (38.79), 41 (39.4), 33 (37.9); Aspiration pneu-
monia: 62 (32.5), 37 (35.6), 25 (28.7); Dehydration: 43 (22.5), 29 (27.9), 14 (16.1); 
Subcutaneous tissue: 30 (15.7), 18 (17.3), 12 (13.8); Infection: 29 (15.2), 21 (20.2), 
8 (9.2); Renal/Genitourinary: 19 (9.9), 14 (13.5), 5 (5.7); Auditory: 16 (8.4), 12 (11.5), 
4 (4.6); Bone: 4 (2.1), 3 (2.9), 1 (1.1) for Total n  191 n(%), ChemoRT n  104 
n(%), RT only n  87 n(%). Note: Four patients received chemotherapy only or 
other/no treatment. CONCLUSIONS: Treatment-related toxicity in patients with 
advanced SCCHN is common. The addition of chemotherapy to radiation is associ-
ated with increased risk treatment-related toxicities. These data provide real-world 
incidence rates of toxicity as observed in clinical practice.
CN7
TREATMENT VARIATION COMPLICATES REAL-WORLD 
PHARMACOECONOMICS: DAILY CLINICAL PRACTICE OF BORTEZOMIB 
IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Franken M1, Gaultney J1, Huijgens P2, Redekop WK1, Uyl-de Groot CA1
1Erasmus University Medical Center, Rotterdam, The Netherlands, 2VU University Medical 
Center, Amsterdam, The Netherlands
OBJECTIVES: The Dutch policy measure on expensive inpatient medicines aims to 
ensure accessibility by relieving ﬁnancial burden of hospitals. After three years, 
outcomes research inﬂuences decision-making on the continuation of additional 
funding. We explored the consequences of daily clinical practice variation for 
real-world pharmacoeconomics of bortezomib in relapsed or refractory multiple 
myeloma. METHODS: Our study included 139 multiple myeloma patients who 
progressed from ﬁrst line therapy and received bortezomib outside of an RCT. 
Detailed case reports were retrospectively collected from medical records in 38% of 
all Dutch hospitals. Treatment variation and combinations of bortezomib were 
explored until sixth line therapy. RESULTS: All patients had at least two treatment 
lines, 66% received third line, 41% fourth line, 14% ﬁfth line and 6% sixth line 
therapy. At least nine chemical agents were given in all lines as mono-therapy or in 
different combinations. No speciﬁc treatment order could be identiﬁed because of large 
variation in regimes and drug usage in different and reversed order. Moreover, guide-
lines have changed over the years and recommend earlier use of bortezomib; and 
lenalidomide, another very effective medicine, was increasingly used. In total, 72 
patients received bortezomib, 30% as mono-therapy and 70% as combination 
therapy. Bortezomib was most often combined with dexamethasone (60%), but com-
binations with ﬁve other drugs were seen. Clinical guidelines state that differences in 
patient circumstances require professional discretion; this results in extensive vari-
ability in daily practice. CONCLUSIONS: Compared to an RCT, outcomes research 
of bortezomib is complicated by extensive treatment variation in daily clinical practice. 
This suggests that a standard pharmacoeconomic model comparing two treatment 
arms is not sufﬁcient. Comprehensive modelling using different data sources is 
required to acquire a valid and precise (cost-) effectiveness measure of bortezomib in 
daily clinical practice.
CN8
METHODOLOGICAL ISSUES OF CONTROL ARM ADJUSTMENTS FOR 
COMPARATIVE EFFECTIVENESS ASSESSMENTS: AN EXAMPLE BASED 
ON THE COMPARISON OF FIRST-LINE BEVACIZUMAB + INTERFERON 
ALPHA-2A VS SUNITINIB IN RENAL CELL CARCINOMA
Schwander B1, Mickisch GH2, Walzer S3, Siebert U4
1AiM GmbH Assessment in Medicine, Schopfheim, Germany, 2Center of Operative Urology 
Bremen, Bremen, Germany, 3F. Hoffmann-La Roche Pharmaceuticals AG, Basel, Switzerland, 
4UMIT—University for Health Sciences, Medical Informatics and Technology, Hall i.T, Austria
OBJECTIVES: Comparative effectiveness assessments require standardization of clini-
cal trial control arms to enable valid indirect comparisons. In order to inform guidelines 
on such adjustments, we provide insights on the Interferon-alpha-2a (IFN-A) control 
arm adjustment performed for comparing bevacizumab (BEV)  Interferon-alpha-2a 
(IFN-A) vs. sunitinib (SUN) in ﬁrst-line metastatic renal-cell cancer. METHODS: 
Adjustments were based on hazard ratios (HR) and median progression-free survival 
(PFS) time. Based on published phase-III trial investigator-assessed PFS (SUN vs. IFN-A 
HR 0.519; SUN PFS 10.8 months [m]; IFN-A 4.1m; BEVIFN-A vs. IFN-A HR 0.630; 
BEV PFS 10.2 m; IFN-A 5.4 m), indirect HRs were recalculated by adjusting IFN-A 
arms applying two scenarios: 1. IFN-A PFS of BEV  SUN IFN-A PFS (4.1 m); 
2. IFN-A PFS of SUN  BEV IFN-A PFS (5.4 m). Applying the cross-trial proportions 
of indirect HRs to direct HRs, the recalculated indirect HRs have been transferred to 
direct HR estimates (cross-trial rule of proportion approach). This approach was tested 
by adjusting the BEV trial IFN-A curve and recalculating the direct HR based on a 
Weibull model, applied to original phase III data. RESULTS: In scenario 1, the HR 
of SUN vs. IFN-A increased to 0.595; in scenario 2 the HR of BEVIFN-A decreased 
to 0.550. Indirect comparison results of SUN vs. BEVIFN-A where comparable for 
both scenarios (HR SUN vs. BEVIFN-A  0.945; CIs: 0.73–1.22; p-value  0.66). 
Testing scenario 2 based on a Weibull-function resulted in HR of BEV  IFN-A 
of 0.517. Applying an updated approach replicating the analysis results for scenario 
2 resulted in an indirect comparison HR of SUN vs. BEVIFN-A of 1.010 (CIs: 
0.79–1.30; p  0.94). CONCLUSIONS: As original trial data are often not accessible, 
using indirect HRs and adjusting them according to the method presented seems 
to be a practicable approach that could be performed based on published data.
PODIUM SESSION II: ECONOMIC EVALUATION AND REIMBURSEMENT 
DECISIONS I
EE1
USING IQWIG’S EFFICIENCY FRONTIER APPROACH FOR THE 
ECONOMIC EVALUATION OF HEAPTITIS C TREATMENT—A PILOT 
AND FEASIBILITY STUDY COMMISSIONED BY IQWIG
Siebert U, Mühlberger N, Conrads-Frank A, Sroczynski G, Schwarzer R
UMIT—University for Health Sciences, Hall, Austria
OBJECTIVES: The German HTA agency IQWiG published new guidelines on health-
economic evaluations for the statutory health care system. The goals of this pilot study 
commissioned by IQWiG were: 1) to apply the efﬁciency frontier (EF) approach 
to evaluate the cost-effectiveness of combination therapy with peginterferon plus 
 ribavirin (PegIFN  RBV) in patients with chronic hepatitis C (CHC); and 2) to assess 
the feasibility of the EF approach in this case example. METHODS: IQWiG’s EF 
approach assesses the cost-effectiveness of the new treatment (i.e., PegIFN  RBV) 
within the speciﬁc disease area (i.e., CHC) by comparing the new treatment’s incre-
mental cost-effectiveness ratio (ICER) to ICERs of established treatments. We used a 
lifetime Markov model to determine health outcomes and costs of all treatment 
options. Health outcomes included sustained virological response (SVR), lifetime risk 
of decompensated cirrhosis and quality-adjusted life years (QALY). Model parameters 
were derived from the published literature and German databases. We adopted the 
perspective of citizens insured through the statutory health insurance. We performed 
a budget impact analysis reporting annual incremental costs. RESULTS: The ICERs 
of PegIFN  RBV compared to interferon plus ribavirin (IFN  RBV) were EUR 
15,000 EUR/SVR avoided, EUR 42,000/decompensated cirrhosis avoided, and EUR 
4,000/QALY. These ICERs are substantially lower than those of the last segments 
of the respective EFs (i.e., ICER of IFN  RBV vs. IFN monotherapy) indicating cost-
effectiveness of PegIFN  RBV. The expected incremental annual budget ranged 
between 15 and 134 million EUR. The introduction of new genotype-speciﬁc treat-
ment guidelines led to cost-savings when compared to IFN  RBV. CONCLUSIONS: 
PegIFN  RBV should be cost-effective compared to other established treatments in 
CHC. The EF approach should be feasible for HTAs in the CHC area. However, 
several issues remain to be solved and the conclusions derived from HTAs based on 
IQWiG’s framework may substantially differ from HTAs assuming uniform willing-
ness-to-pay thresholds across the entire health care system.
EE2
DEAR POLICYMAKER: HAVE YOU MADE UP YOUR MIND?
Koopmanschap M1, Stolk E2, Koolman XH3
1Erasmus MC, Rotterdam, The Netherlands, 2Erasmus Medical Center, Rotterdam, The 
Netherlands, 3Delft University of Technology, Delft, The Netherlands
OBJECTIVES: To get insight in what criteria as presented in HTA studies are impor-
tant for decision makers in health care priority setting. METHODS: We performed a 
